This partnership represents a strategic move to address drug resistance in AML, leveraging AmMax's antibody expertise and Lonza's advanced ADC technology. The collaboration aims to deliver a more effective treatment option for patients with significant unmet medical needs.
Problem: Addressing Venetoclax/Azacitidine Resistance in AML
Acute myeloid leukemia (AML) remains one of the most challenging hematological cancers to treat, particularly due to the emergence of resistance to standard therapies like venetoclax and azacitidine. This resistance significantly limits treatment efficacy and patient outcomes. AmMax Bio, a clinical-stage biopharmaceutical company, identified this critical unmet need and sought to develop a novel solution.
Solution: AMB-104 Leveraging Lonza's SYNtecan™ Platform
AmMax Bio engineered AMB-104, an antibody-drug conjugate (ADC) that combines their clinically-validated monoclonal antibody with Lonza's exatecan-based SYNtecan™ linker-payload platform. This platform is designed to enhance ADC tolerability and efficacy, addressing the key challenges of drug resistance in AML.
Under the terms of the non-exclusive licensing agreement:
- AmMax gains access to Lonza's SYNtecan™ technology. - Lonza will manufacture components related to the licensed technologies. - AmMax retains responsibility for research, development, manufacturing, and commercialization of the ADC. - Lonza, through an affiliated company, is eligible for upfront payments, potential milestone payments, and royalties on net sales of resulting products.
"The continued evolution of the ADC landscape underscores the demand for robust, differentiated technologies that unlock the differentiated therapeutic potential of novel ADCs," said Jan Vertommen, Vice President of Commercial Development at Lonza. "Our collaboration with AmMax reflects this market development, and we are pleased to support their program across the development phases."
Results: A Promising New Weapon Against AML
The partnership aims to leverage the strengths of both companies to deliver a more effective treatment for AML. Key outcomes include:
- **Targeted Cytotoxic Payload**: AMB-104 is designed to directly kill monocytic AML cells, offering a more precise approach to tackling drug-resistant cancer cells. - **Clinical Development**: AmMax plans to submit an Investigational New Drug (IND) application in early 2027, indicating a clear path forward for clinical trials. - **Market Potential**: The collaboration positions both companies to capitalize on the growing demand for advanced ADC therapies in oncology.
Larry Hsu, Ph.D., Chairman and CEO of AmMax, emphasized the strategic importance of the partnership: "We are excited to leverage Lonza's validated conjugation and linker-payload technologies with our monoclonal antibody to optimize the therapeutic potential of AMB-104. We look forward to advancing AMB-104 through clinical trials and benefitting patients with significant unmet medical needs."
Technical Details
- **AMB-104**: An ADC combining AmMax's monoclonal antibody with Lonza's SYNtecan™ linker-payload platform. - **SYNtecan™ Platform**: Clinically-validated technology known for enhancing ADC tolerability and efficacy. - **Licensing Agreement**: Non-exclusive, with Lonza eligible for upfront, milestone, and royalty payments. - **Development Timeline**: IND submission planned for early 2027.
Is this your company?
This article features your business. Claim it to add your logo, contact details, and a link to your website — or upgrade to reach more buyers.
Did you know 80% of Press Releases trigger AI content warnings? Reach out and the M4S team can assist.